Fox Run Management, L.L.C. Protagonist Therapeutics, Inc Transaction History

Fox Run Management, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$14.05 - $23.44 $439,413 - $733,086	31,275 New	31,275 $717,000
Q2 2023 Aug 11, 2023	BUY	$18.02 - $29.36 $503,316 - $820,054	27,931 New	27,931 $771,000
Q4 2022 Feb 07, 2023	SELL	$7.36 - $11.17 $86,207 - $130,834	-11,713 Reduced 28.79%	28,970 $316,000
Q3 2022 Nov 07, 2022	BUY	$7.86 - $11.71 $319,768 - $476,397	40,683 New	40,683 $343,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.